Viridian Therapeutics, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Viridian Therapeutics, Inc./DE (VRDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $100.00K, a 50.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $6.70M, a 570.00% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $200.00K.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $1.00M.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $8.10M, a 118.92% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.70M, a 81.86% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $20.40M.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $100.00K, a 93.75% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|
| 2026-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.80M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.70M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $8.10M 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.20M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $3.70M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $20.40M 10-K · filed 2026-02-26 | ||
| 2019-12-31 | $100.00K 10-K · filed 2020-03-13 | ||
| 2018-12-31 | $1.60M 10-K · filed 2020-03-13 | ||
| 2017-12-31 | $3.80M 10-K · filed 2019-03-14 | ||
| 2016-12-31 | $800.00K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |